億勝生物科技(01061.HK)2021年營收淨利雙增，多項研發計劃處於臨牀階段
格隆匯3月22日丨億勝生物科技(01061.HK)公佈年度業績，截至2021年12月31日止12個月，公司營業額為16.38億港元，同比增長67.4%；公司擁有人應占溢利為3.46億港元，同比增長58.0%，基本每股盈利為60.00港仙，每股末期息為5.5港仙，全年合計派9.5港仙。
集團的營業額主要由眼科及外科(創傷護理及修復)分部組成。各分部中目前具有增長動力的核心產品為：眼科—貝復舒系列(貝復舒滴眼液、貝復舒眼用凝膠及貝復舒單劑量滴眼液)、妥布黴素滴眼液、左氧氟沙星滴眼液、玻璃酸鈉滴眼液及適麗順®；及外科(創傷護理及修復)—貝復濟系列(貝復濟液體制劑、貝復濟凍乾粉及貝復新凝膠)、Carisolv®齲齒凝膠、伢典醫生漱口水及伊血安顆粒。眼科及外科的分部營業額分別約佔集團營業額的41.1%及58.9%。
集團的旗艦生物藥貝復舒系列及貝復濟系列(以成纖維細胞生長因子(bFGF)為基礎的生物藥)的合併營業額約佔集團總營業額的84.3%，其中貝復舒系列及貝復濟系列分別佔集團營業額的26.1%及58.2%。集團營業額的餘下15.7%主要來自銷售妥布黴素滴眼液、左氧氟沙星滴眼液、玻璃酸鈉滴眼液、適麗順®、Carisolv®齲齒凝膠、伢典醫生漱口水及伊血安顆粒的共同貢獻。
研發方面，建立吹-灌-封平台構成集團的部分核心競爭力，亦可藉此開發及生產一系列不含防腐劑單劑量藥品。於2021年12月31日，集團的產品管線包括4種已商業化的不含防腐劑單劑量滴眼液。於回顧年度，集團已獲得不含防腐劑單劑量鹽酸莫西沙星滴眼液在中國註冊及商業化的批准。預期部分尚在開發的不含防腐劑單劑量眼科藥品將於未來二至五年內商業化。
於2021年12月31日，共有15項研發計劃處於臨牀前至臨牀階段，其中3項眼科計劃處於臨牀階段。於公佈日期，集團持有合共44份專利證書或授權書，包括35項發明專利、4項實用新型專利及5項外觀專利。集團目前已將其研發資源多元化至珠海(中國)、波士頓(美國)、倫敦(英國)及新加坡的多個研究基地，其不僅支持集團對新療法的追求，亦支持我們對全球人才的獲取。
此外，集團一直不懈投入資源積蓄及強化其市場渠道能力。於2021年12月31日，集團於中國部署43間地區銷售辦事處網絡及總數約1,265名銷售人員及營銷代表，其中64%為全職員工及36%為合約人員或代理聘請人員。集團於2020年擴大在新加坡的業務，將其作為擴展東南亞國家市場渠道的基地。於回顧年度，集團的治療產品主要於中國主要城市、省份及縣城的逾10,500家醫院及醫療機構以及約2,110家藥房處方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
